News about Biotechnology, Pharmaceutical and Healthcare

00:20 EDT 5th July 2015 | BioPortfolio

Latest news articles in the life-science, healthcare, medical device, biotechnology and pharmaceuticals sectors. 

Showing News Articles 1–25 of 9,500+

Saturday 4th July 2015

Cyprotex invests for new markets at Alderley Park

Cyprotex, the Macclesfield-based drug analysis specialist, is investing in its new space at the BioHub at Alderley Park.In a stock market statement it said it was expanding its bioanalytical capabilities at the new science cluster near Alderley Edg...

£45M Industrial Biotechnology Catalyst – Round 2 Call for Proposals Now Open

This is a major opportunity for the pharma and IB sector. Up to £45M has been committed in 2014-15 for R&D to address one or more of the major challenges using biological processes, or processes in which biological and chemical approaches...

Professor Alan Boyd Elected President of the Faculty of Pharmaceutical Medicine

Professor Alan Boyd, owner of Boyds consultancy business, has been elected as President of the Faculty of Pharmaceutical Medicine. Professor Boyd, who is currently Vice President of the Faculty, will take up office on 19th November 2015.Commenting on...

Friday 3rd July 2015

Nivolumab granted positive scientific opinion under UK early access scheme

Nivolumab, a new lung cancer drug, has been granted a positive scientific opinion by the UK medicines safety regulator under the Early Access to Medicines Scheme (EAMS).

Study finds favour in self-monitoring for patients on oral anticoagulants

People using oral blood thinning therapy such as warfarin can successfully monitor and manage their own international normalised ratio (INR) using commercially available devices, research shows.

Rise of antipsychotic drug use in 13–24 year olds in United States

–The use of antipsychotic drugs by young people aged 13–24 years has risen in the United States between 2006 and 2010 but has fallen in those aged between 1–12 years of age, according to research published in JAMA Psychiatry. 

Vertex’s cystic fibrosis drug gets FDA approval

Vertex Pharmaceuticals cystic-fibrosis drug Orkambi, which could treat as many as 8,500 patients in the US, has been approved by the FDA. At an astonishing annual wholesale cost of $259,000 per patient, Orkambi (lumacaftor and ivacaftor) is aimed at treating patients with the F508del genetic mutation, the underlying cause of cystic fibrosis (CF). The mutation affects the function of the lungs and ...

Astrazeneca to Collaborate with Inserm in Type 2 Diabetes and Chronic Kidney Disease Studies

AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches to type 2 diabetes and Chronic Kidney Disease (CKD). The aim of the collaboration is to advance understanding of the biological mechanisms that underpin these conditions and develop new treatments based on this knowled...

Quotient Clinical Delivers Breakthrough First-in-Human Program for Corcept Therapeutics

Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated, focusing on a next generation selective glucocorticoid receptor antagonist (CORT125134) in development for the treatment of Cushing’s syndrome and certain cancers. The Enable...

Sanofi’s Toujeo approved in Japan

The Ministry of Health, Labor and Welfare in Japan has given Sanofi a marketing authorisation for the diabetes drug the Swiss firm hopes will be the successor to its blockbuster Lantus. Sanofi will market the new insulin glargine injection as Lantus XR in Japan, while it is known as Toujeo in the US and Europe, where it is already approved by the FDA, the EMA, and Health Canada. Image capti...

Astellas in ‘unacceptable’ Xtandi ABPI code breach

The industry code of conduct regulator has singled out Astellas for ‘particular censure’ for arranging a meeting for UK healthcare professional to promote the use of Xtandi. It found that Astellas had breached the ABPI code by paying clinicians to attend a European meeting for urologists and oncologists that was not a ‘genuine advisory board meeting’. Image caption:  ...

Perfect Partners for Excellent ELISAs

New Matched Antibody Pairs Setting up your own high quality, customised immunoassay solutions just became quicker, easier and more cost-effective. The new range of distinctive, top-quality, pre-matched capture and detection antibody pairs manufactured by BioPorto is now available from Alpha Laboratories. Each pair consists of a capture antibody and biotinylated detection antibody, custom matched t...

Graphene Set to Make Waves in Multiple Markets Due to its Innovative Capabilities and High Performance

Strong characteristics can put graphene ahead of carbon nanotubes in most application segments, finds Frost & Sullivan Carbon nanotubes and graphene have been competing head-to-head for many of the same applications in recent years. For most applications, the development of carbon nanotubes has been gradually rising as evidenced by patent trends. Nevertheless, graphene has been making drastic ...

Thursday 2nd July 2015

Norway, biosimilars in different funding systems

Norway has approved biosimilar versions of the biologicals somatropin, epoetin, filgrastim and infliximab. Epoetin and filgrastim are included in a national tender for drugs used in hospitals, in which prices can be reduced by up to 89%. Regional hea...

Effect of co-insurance and reference pricing on generics entry

To study the impact of reference pricing on generics entry Brekke and co-authors developed a novel Salop-type model where a brand-name producer competes with several generics makers in terms of prices [1].

Biosimilars substitution bill become law in Texas

Texas is the latest US state to pass a law that will allow the substitution of biosimilars at the pharmacy level. To date, thirteen states have passed legislation requiring prescriber communication and record keeping for biosimilars [1].

Generics prices in US decrease again in 2013

In 2013, retail prices for 280 widely used generics fell by an average of 4.0%, compared to the US inflation rate, which was 1.5% over the same period.

Biosimilars licensing agreements for AMP and Formycon

German biosimilars companies AMP Biosimilars (AMP) and Formycon have both made out-licensing agreements for their candidate biosimilars.

Indian pharma industry to get government support

In a bid to promote the manufacture of pharmaceuticals in the country, the Indian Government has announced plans to set up a Rs 500-crore venture capital fund to provide cheaper loans to firms looking to establish or upgrade manufacturing facilities.

Polish firm gets EIB loan for biosimilars development

The European Investment Bank (EIB) is lending Euros 45 million (around Zloty 185 million) to the largest Polish manufacturer of pharmaceuticals, Polpharma, for its research into, and development of, biosimilars.

Mylan launches generic asthma inhaler in UK

US generics manufacturer Mylan announced on 8 June 2015 that it had launched the first bioequivalent alternative to GlaxoSmithKline (GSK)’s asthma inhaler Seretide/Advair (fluticasone/salmeterol) in the UK.

Recurrence of Ebola transmission in Liberia

On 9 May 2015, Liberia marked an important milestone in the management of their Ebola outbreak. On that day, the country was declared free of Ebola transmission because no new cases had been identified for 42 days after the safe burial of the last person confirmed to have been infected with Ebola virus disease. Although transmission of the virus had ceased, Liberia remained at high risk of a rec...

Biogen looks to build $1.1bn manufacturing plant in Switzerland

Biotech company Biogen plans to invest one billion Swiss francs ($1.1bn) in Solothurn, Switzerland to build a new production plant that will create about 400 new jobs beginning in 2019.

Unilever to acquire Murad skin care brand

Antoinette AlexanderUnilever remains hot on the acquisition trail as it has signed an agreement to acquire clinical skin care brand Murad, which was developed by Howard Murad, a dermatologist, pharmacist and UCLA professor. read more

GiftStarter looks to take hassle out of gift giving

Mike TroyA recently launched gifting website with a familiar sounding name promises to make it better to receive than give a gift.   read more



Advertisement
 
Advertisement